| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research |
1 Department of Radiology, Loma Linda University Medical Center, 11234 Anderson
St., MC Room 2605, Loma Linda, CA 92354.
2 Department of Surgery, Transplant Division, Loma Linda University Medical
Center, Loma Linda, CA.
3 Department of Medicine, Nephrology Division, Loma Linda University Medical
Center, Loma Linda, CA.
OBJECTIVE. Nephrogenic systemic fibrosis (NSF) is a rare multisystemic fibrosing disorder that principally affects the skin but may affect other organs of patients with renal insufficiency. The purpose of our study was to identify any common risk factors and determine whether IV gadodiamide is associated with the development of NSF.
MATERIALS AND METHODS. A retrospective chart review was performed for all 12 patients diagnosed with NSF at our institution between 2000 and 2006 to identify the clinical manifestations, timing, and dose of gadodiamide administration; dialysis records; concurrent medications; comorbid conditions and surgeries; laboratory findings; imaging findings; and clinical outcome. A review of the dialysis and MR records between 2000 and 2006 showed 559 MRI examinations on 168 dialysis patients (including 301 contrast-enhanced examinations).
RESULTS. NSF was diagnosed by clinical findings and tissue diagnosis. All 12 patients had renal insufficiency—eight with dialysis-dependent chronic renal insufficiency and four with acute hepatorenal syndrome. All 12 patients developed skin fibrosis within 2-11 weeks after gadodiamide administration. The odds ratio for development of NSF after gadodiamide exposure was 22.3. No other common event or exposure could be found. Four patients had abnormal scintigraphic bone scans with skin and muscle uptake and lower-extremity MRI finding of edema in the muscles, intermuscular fascia, and skin. Despite the fact that 10 patients were dialyzed within 2 days of gadodiamide administration, this did not prevent the development of NSF.
CONCLUSION. Development of NSF was strongly associated with gadodiamide administration in the setting of either acute hepatorenal syndrome or dialysis-dependent chronic renal insufficiency.
Keywords: dialysis • MR contrast agents • MR imaging • nephrogenic systemic fibrosis • nuclear medicine • renal disease
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. Prince, H. Zhang, M. Morris, J. L. MacGregor, M. E. Grossman, J. Silberzweig, R. L. DeLapaz, H. J. Lee, C. M. Magro, and A. M. Valeri Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers Radiology, September 1, 2008; 248(3): 807 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Habibi, M. S. Krishnam, D. G. Lohan, F. Barkhordarian, M. Jalili, R. S. Saleh, S. G. Ruehm, and J. P. Finn High-Spatial-Resolution Lower Extremity MR Angiography at 3.0 T: Contrast Agent Dose Comparison Study Radiology, August 1, 2008; 248(2): 680 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bayliss, W. Jacobs, and M. Williams Renal failure and abdominal pain as the presenting symptoms of a rare tumor of the aorta masquerading as a calcified plaque NDT Plus, July 12, 2008; (2008) sfn101v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Pieringer, S. Schumacher, B. Schmekal, T. Gitter, and G. Biesenbach Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure NDT Plus, June 1, 2008; 1(3): 193 - 194. [Full Text] [PDF]
|
|
|
|
|
|
N. M. Rofsky, A. D. Sherry, and R. E. Lenkinski Nephrogenic Systemic Fibrosis: A Chemical Perspective Radiology, June 1, 2008; 247(3): 608 - 612. [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsushima, A. Takahashi-Taketomi, and K. Endo Nephrogenic Systemic Fibrosis in Japan: Advisability of Keeping the Administered Dose as Low as Possible Radiology, June 1, 2008; 247(3): 915 - 916. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Reilly Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term Hemodialysis Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 747 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. Kim, R. A. Mirza, J. A. Bryant, E. D. Whiting, D. M. Delong, C. E. Spritzer, and E. M. Merkle Central Veins of the Chest: Evaluation with Time-resolved MR Angiography Radiology, May 1, 2008; 247(2): 558 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Wiginton, B. Kelly, A. Oto, M. Jesse, P. Aristimuno, R. Ernst, and G. Chaljub Gadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in Tissue Am. J. Roentgenol., April 1, 2008; 190(4): 1060 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Golding and J. M. Provenzale Nephrogenic Systemic Fibrosis: Possible Association with a Predisposing Infection Am. J. Roentgenol., April 1, 2008; 190(4): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Soulez, M. Pasowicz, G. Benea, L. Grazioli, J. P. Niedmann, M. Konopka, P. C. Douek, G. Morana, F. K. W. Schaefer, A. Vanzulli, et al. Renal Artery Stenosis Evaluation: Diagnostic Performance of Gadobenate Dimeglumine-enhanced MR Angiography--Comparison with DSA Radiology, April 1, 2008; 247(1): 273 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Shabana, R. H. Cohan, J. H. Ellis, H. K. Hussain, I. R. Francis, L. D. Su, S. K. Mukherji, and R. D. Swartz Nephrogenic Systemic Fibrosis: A Report of 29 Cases Am. J. Roentgenol., March 1, 2008; 190(3): 736 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. ISSA, E. D. POGGIO, R. A. FATICA, R. PATEL, P. M. RUGGIERI, and R. J. HEYKA Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 95 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Horger, G. Fierlbeck, J. Kuemmerle-Deschner, N. Tzaribachev, M. Wehrmann, C. D. Claussen, and J. Fritz MRI Findings in Deep and Generalized Morphea (Localized Scleroderma) Am. J. Roentgenol., January 1, 2008; 190(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. U. Herborn, V. M. Runge, D. M. Watkins, J. M. Gendron, and L. G. Naul MR Angiography of the Renal Arteries: Intraindividual Comparison of Double-Dose Contrast Enhancement at 1.5 T with Standard Dose at 3 T Am. J. Roentgenol., January 1, 2008; 190(1): 173 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Leyendecker, C. E. Barnes, and R. J. Zagoria MR Urography: Techniques and Clinical Applications RadioGraphics, January 1, 2008; 28(1): 23 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Dillman, J. H. Ellis, R. H. Cohan, P. J. Strouse, and S. C. Jan Frequency and Severity of Acute Allergic-Like Reactions to Gadolinium-Containing IV Contrast Media in Children and Adults Am. J. Roentgenol., December 1, 2007; 189(6): 1533 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kahana, M. J. Lucarelli, A. M. Grayev, J. J. Van Buren, C. N. Burkat, and L. R. Gentry Noninvasive Dynamic Magnetic Resonance Angiography With Time-Resolved Imaging of Contrast KineticS (TRICKS) in the Evaluation of Orbital Vascular Lesions Arch Ophthalmol, December 1, 2007; 125(12): 1635 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L A Ratnam, S R Nelson, and A M Belli Investigating progressive unexplained renal impairment and hypertension BMJ, November 24, 2007; 335(7629): 1094 - 1096. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Nortier and V. del Marmol Nephrogenic systemic fibrosis the need for a multidisciplinary approach Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3097 - 3101. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Lohan, F. Barkhordarian, R. Saleh, M. Krishnam, N. Salamon, S. G. Ruehm, and J. P. Finn MR Angiography at 3 T for Assessment of the External Carotid Artery System Am. J. Roentgenol., November 1, 2007; 189(5): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thurnher, S. Miller, G. Schneider, C. Ballarati, G. Bongartz, C. U. Herborn, S. Schoenberg, M. A. Cova, G. Morana, K. Niazi, et al. Diagnostic Performance of Gadobenate Dimeglumine Enhanced MR Angiography of the Iliofemoral and Calf Arteries: A Large-Scale Multicenter Trial Am. J. Roentgenol., November 1, 2007; 189(5): 1223 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shiehmorteza, R. F. Hanna, and M. S. Middleton Can Gadopentetate Dimeglumine Be Safely Administered More Rapidly Than the FDA-Approved Injection Rate for Liver Imaging? Am. J. Roentgenol., October 1, 2007; 189(4): W231 - W231. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Broome, A. C. Cottrell, and E. Kanal Response to "Will Dialysis Prevent the Development of Nephrogenic Systemic Fibrosis After Gadolinium-Based Contrast Administration?" Am. J. Roentgenol., October 1, 2007; 189(4): W234 - W235. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Collidge, P. C. Thomson, P. B. Mark, J. P. Traynor, A. G. Jardine, S. T. W. Morris, K. Simpson, and G. H. Roditi Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort Radiology, October 1, 2007; 245(1): 168 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Swaminathan and S. V. Shah New Insights into Nephrogenic Systemic Fibrosis J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2636 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Gibbons, P. A. Araoz, and E. E. Williamson The Year in Cardiac Imaging J. Am. Coll. Cardiol., September 4, 2007; 50(10): 988 - 1003. [Full Text] [PDF]
|
|
|
|
|
|
T. C. Lauenstein, K. Salman, R. Morreira, T. Heffron, J. R. Spivey, E. Martinez, P. Sharma, and D. R. Martin Gadolinium-Enhanced MRI for Tumor Surveillance Before Liver Transplantation: Center-Based Experience Am. J. Roentgenol., September 1, 2007; 189(3): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Saab, A. Abu-Alfa, E. A. Sadowski, and A. Djamali Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology, September 1, 2007; 244(3): 930 - 932. [Full Text] [PDF]
|
|
|
|
|
|
G. Saab and A. Abu-Alfa Will Dialysis Prevent the Development of Nephrogenic Systemic Fibrosis After Gadolinium-Based Contrast Administration? Am. J. Roentgenol., September 1, 2007; 189(3): W169 - W169. [Full Text] [PDF]
|
|
|
|
|
|
P. C Thomson, T. A Collidge, P. B Mark, and J. P Traynor Gadolinium contrast may be risky in kidney disease BMJ, June 30, 2007; 334(7608): 1335 - 1336. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Stanley Our Practice of Radiology: Reflections on its Growth and Stature Am. J. Roentgenol., June 1, 2007; 188(6): 1439 - 1439. [Full Text] [PDF]
|
|
|
|
|
|
E. Kanal, A. J. Barkovich, C. Bell, J. P. Borgstede, W. G. Bradley Jr., J. W. Froelich, T. Gilk, J. R. Gimbel, J. Gosbee, E. Kuhni-Kaminski, et al. ACR Guidance Document for Safe MR Practices: 2007 Am. J. Roentgenol., June 1, 2007; 188(6): 1447 - 1474. [Full Text] [PDF]
|
|
|
|
|
|
H. S. Thomsen and S. K. Morcos Nephrogenic Systemic Fibrosis and Nonionic Linear Chelates Am. J. Roentgenol., June 1, 2007; 188(6): W580 - W580. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Broome and M. S. Girguis Reply Am. J. Roentgenol., June 1, 2007; 188(6): W581 - W581. [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Ng, R.-C. Lee, S.-H. Shen, and G. Kirk Gadolinium-Associated Nephrogenic Systemic Fibrosis: Double Dose, Not Single Dose Am. J. Roentgenol., June 1, 2007; 188(6): W582 - W582. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Broome and M. S. Girguis Reply Am. J. Roentgenol., June 1, 2007; 188(6): W583 - W583. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Karlik Gadodiamide-Associated Nephrogenic Systemic Fibrosis Am. J. Roentgenol., June 1, 2007; 188(6): W584 - W584. [Full Text] [PDF]
|
|
|
|
|
|
H. P. Forman Back to the Beginning Am. J. Roentgenol., February 1, 2007; 188(2): 295 - 296. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
